Cercar
24/09/2024
Escalating costs of innovative medicines: perspective and proposals
Vallano, A, Pontes, C. Escalating costs of innovative medicines: perspective and proposals. Frontiers in Public Health. 2024; 12DOI:10.3389/fpubh.2024.1449707. PMID:39381757. IF:3.400(Q1/2D).
14/06/2024
Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication: A Population-Based Cohort Study
Ríos, J, Sapena, V, Marino, Z, Bruix, J, Forns, X, Morros, R, Reig, M, Torres, F, Pontes, C. Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication: A Population-Based Cohort Study. Drugs-Real World Outcomes. 2024; 11(3)DOI:10.1007/s40801-024-00437-y. PMID:38874848. IF:(Q/D).
01/06/2024
Cardiometabolic sex-specific response to a natural polysaccharide in individuals with obesity
Villaplana, VDS, Muñoz, N, Puntes, M, Badimón, L, Padró, T. Cardiometabolic sex-specific response to a natural polysaccharide in individuals with obesity. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2024; 54DOI:. PMID:. IF:3.600(Q1/2D).
24/04/2024
First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug
Pieren, M, Gutiérrez-Solana, AA, Arbós, RMA, Boyle, GW, Davila, M, Davy, M, Gitzinger, M, Husband, L, Martínez-Martínez, MS, Mazarro, DO, Pefani, E, Penman, SL, Remuiñán, MJ, Vlasakakis, G, Zeitlinger, M, Dale, GE. First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2024; 79(6)DOI:10.1093/jac/dkae107. PMID:38656557. IF:3.600(Q2/3D).